Agile Therapeutics
AGRX
$0.36
Share price
-0.82%
Change (1 day)
-90.30%
Change (1 year)
Categories
Agile Therapeutics (AGRX) - Cash on Hand
Cash on Hand as of March 2024 : $2.61 M
According to Agile Therapeutics
's latest financial reports the company has $2.61 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Agile Therapeutics - Cash on Hand chart (from 2013 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $5.24 M | -72.6% |
| 2021-12-31 | $19.14 M | -64.86% |
| 2020-12-31 | $54.47 M | 57.98% |
| 2019-12-31 | $34.47 M | 339.17% |
| 2018-12-31 | $7.85 M | -78.16% |
| 2017-12-31 | $35.95 M | -26.25% |
| 2016-12-31 | $48.75 M | 41.74% |
| 2015-12-31 | $34.39 M | -14.4% |
| 2014-12-31 | $40.18 M | 1795.69% |
| 2013-12-31 | $2.11 M | -89.41% |
| 2012-12-31 | $20.01 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $26.21 B | 1,002,500.38% | 🇺🇸 USA |
 Pfizer PFE | $11.92 B | 456,075.91% | 🇺🇸 USA |
 Merck MRK | $5.61 B | 214,775.72% | 🇺🇸 USA |
 TherapeuticsMD TXMD | $4.33 M | 65.89% | 🇺🇸 USA |
 Antares Pharma ATRS | N/A | N/A | 🇺🇸 USA |